



sasdt

SA SOCIETY OF  
DAIRY TECHNOLOGY

# Agenda



- 17:30 Members arrival
- 18:00 Welcome, Attendance register, House rules
- 18:05 Explaining the New SASDT from 2024
- 18:10 Upcoming dates: Year End Function, IDF session in 2024
- 18:15 Speaker introduction - Prof. Renée Blaauw
- 18:20 Talk - Dairy Matrix: Not All Fats Are The Same
- 18:50 Questions
- 18:55 Summary and thank you
- 19:00 Canapes, drinks and networking
- 21:00 Close

# House Rules



The SASDT expect and encourage its members and visitors to its meetings, to uphold the letter and spirit of the Competition Act no 89 of 1998. Attendees will ensure that no confidential information from their respective organizations are either discussed, revealed, divulged, whether directly, by intent or omission. By signing the attendance register all attendees acknowledges their compliances herewith.



# SASDT – 2024 and beyond

Dismantling of regional committees

National committee with different work groups

Updated constitution following strategy

## Vision

The SASDT's vision is to bring science and technology to the Dairy Industry.

## Mission

The South African Society of Dairy Technology (SASDT) is an active society whose primary objective is to assimilate and share technological and scientific advancement amongst our members who are key role players in our national dairy sector.

## Organisational objectives

- To provide a platform to promote technological and scientific advancement in the dairy industry
- To build a strong, active membership basis that includes secondary and primary dairy stakeholders



# Important Dates – SASDT & DSA

| <b>Month</b> | <b>Date</b> | <b>Event</b>      | <b>Region</b>     | <b>Venue</b> |
|--------------|-------------|-------------------|-------------------|--------------|
| Oct-23       | 25th        | Webinar           | DSA               | Online       |
| Nov-23       | 22nd        | Webinar           | DSA               | Online       |
|              | 30th        | Year-End Function | Western Cape      | TBA          |
| Dec-23       | 1st         | Year-End Function | Northern Division | TBA          |
|              | 4th         | Webinar           | DSA               | Online       |



# Speaker – Prof. Renée Blaauw

PhD (Nutritional Sciences) is a Professor in Therapeutic Nutrition at the Division of Human Nutrition, Stellenbosch University, South Africa.

She is a registered dietitian with the Health Professions Council of South Africa. She is a Past Chairperson of the Professional Board for Dietetics in South Africa, a Past President of SASPEN and an honorary member of both SASPEN and ADSA. She is currently serving as the Scientific Secretary of SASPEN.

Her main research interests include Nutrition support of critically ill patients; Nutritional management of gastro-intestinal diseases and Hospital malnutrition. To this effect she is a member of the GLIM (Global Leadership Initiative on Malnutrition) working group and endeavours to contribute to the evidence-base regarding adult hospital malnutrition in South Africa.

She is actively involved in teaching and training in dietetics, with a passion for mentoring. She strives to fulfil her educational philosophy “***To stimulate, create interest and empower others to help themselves***”.





**Stellenbosch**

UNIVERSITY  
IYUNIVESITHI  
UNIVERSITEIT

forward together  
sonke siya phambili  
saam vorentoe

# Not all fats are the same

Special reference to dairy and Cardiovascular disease

**Renée Blaauw**

SADT WC Meeting 28 September 2023

# Disclaimer



- I serve on the Technical Advisory Committee for the Consumer Education project of Milk SA
- I declare no conflict of interest which might have interfered with the scientific validity of this presentation



# Discussion points




- Prevalence of NCD and cardiometabolic risk factors
- Consensus dietary recommendations
  - Dietary patterns
- Investigate some evidence
- Making sense of it all
- Concluding remarks

# Non-communicable disease burden in SA

**NATIONAL STRATEGIC PLAN  
FOR THE PREVENTION AND CONTROL  
OF NON-COMMUNICABLE DISEASES**

**2022 – 2027**

Group II – non-communicable diseases – accounts for the highest proportion of deaths.











The Group I category comprises three kinds of illness:

- Infections (communicable diseases);
- Maternal and child conditions;
- Nutritional causes of death.

Accidents account for a high percentage of people who are living with disabilities.



# NCD burden



[2009; 2013; 2016]

**WCP Burden of Disease Report 2019**

# Cardiometabolic risk factors



## Dyslipidemia

Raised LDL-  
cholesterol

Decreased  
HDL-  
cholesterol

Raised TG

## Clinical features

Insulin  
resistance

Subclinical  
inflammation

Hypertension

Vascular  
dysfunction

Impaired  
coagulation

## Lifestyle- related

Obesity

Inactivity


Smoking

Alcohol


Unhealthy diet

# Current dietary guidelines

↓ Total fat and saturated fat



↑ LDL-cholesterol



↑ Atherosclerotic risk

## ■ International Dietary Guidelines

- Control dietary fat intake
- Intake of SFA's should be < 10% of total energy intake



Healthy dietary patterns

# Healthy dietary pattern



Contains higher intakes of fruit, vegetables, whole grains, low-fat or non-fat dairy, seafood, nuts and legumes. Moderate intake of alcohol and a lower intake of red and processed meat and low in sugar and sugar-sweetened foods and beverages, as well as refined grains.

# Healthy dietary pattern



Contains higher intakes of fruit, vegetables, whole grains, **low-fat or non-fat dairy**, seafood, nuts and legumes. Moderate intake of alcohol and a lower intake of red and processed meat and low in sugar and sugar-sweetened foods and beverages, as well as refined grains.

# SA Dyslipidaemia Guidelines



## **South African dyslipidaemia guideline consensus statement: 2018 update**

A healthy diet is one of moderation that is nutrient dense, and which emphasises adequate intake of fruits, vegetables, whole grains, legumes and nuts, and limits consumption of refined grains, processed foods, added sugar and sodium, and saturated and trans fats.





***What is the evidence regards to  
dairy intake and CVD?***




# Cheese consumption and risk for CVD

- Assessing effect of cheese consumption on risk for CVD, CHD and stroke
  - 15 studies included
  - Mean study duration 10 years

## Relative Risk for high versus low cheese consumption

- RR=0.90 for CVD
- RR=0.86 for CHD
- RR=0.90 for stroke

**Protective effect**



# Total dairy intake and CVD risk



J Cardiovasc Thorac Res, 2017, 9 (1), 1-11

doi: 10.15171/jcvtr.2017.01

<http://journals.tbzmed.ac.ir/jcvtr>



## *Review Article*



## The effect of dairy consumption on the prevention of cardiovascular diseases: A meta-analysis of prospective studies

Fatemeh Gholami<sup>1</sup>, Malihe Khoramdad<sup>2</sup>, Nader Esmailnasab<sup>3\*</sup>, Ghobad Moradi<sup>3</sup>, Bijan Nouri<sup>3</sup>, Saeid Safiri<sup>4</sup>, Yousef Alimohamadi<sup>5,6</sup>

- Meta-analysis on 27 prospective cohort studies, published until 2014

**AIM:** To determine relationship between total dairy intake and Cardiovascular disease




# Total dairy intake and CVD risk



## Conclusion:


- Inverse association between total dairy intake and CVD and Stroke
- Protective role of dairy shown



Gholami et al, 2017

397

CVD events 10% reduction







NOTE: Weights are from random effects analysis

24

Stroke events 12% reduction

*Review*

# Consumption of Dairy Foods and Cardiovascular Disease: A Systematic Review

Annalisa Giosuè <sup>1,†</sup> , Ilaria Calabrese <sup>1,†</sup> , Marilena Vitale <sup>1</sup> , Gabriele Riccardi <sup>1</sup> and Olga Vaccaro <sup>2,\*</sup> 

- Included data published until April 2021
- 37 prospective cohort studies or RCT's included

# Total dairy

| 200g / 200ml          | Meta-Analysis            | Neutral Relation        | Inverse Relation<br>(% Risk Reduction) | Positive Relation<br>(% Risk Increase) |
|-----------------------|--------------------------|-------------------------|--|--|
| CHD incidence         | Soedamah-Muthu 2011 [23] | ✓                       |  |  |
|                       | Qin 2015 [21]            | ✓                       |  |  |
|                       | Alexander 2016 [22]      | (high vs. low intake) ✓ | ✓<br>(-14% per > 3 s/d)                |  |
|                       | Guo 2017 [19]            | ✓                       |  |  |
|                       | Soedamah-Muthu 2018 [24] | ✓                       |  |  |
|                       | Bechthold 2019 [25]      | ✓                       |  |  |
| CHD mortality         | Mazidi 2019 [26]         | ✓                       |  |  |
| <b>FULL-FAT DAIRY</b> |                          |                         |  |  |
| All-cause mortality   | Guo 2017 [19]            | ✓                       |  |  |
| CVD incidence         | Guo 2017 [19]            | ✓                       |  |  |
| CHD incidence         | Soedamah-Muthu 2011 [23] | ✓                       |  |  |
|                       | Qin 2015 [21]            | ✓                       |  |  |
|                       | Alexander 2016 [22]      | ✓                       |  |  |
|                       | Guo 2017 [19]            | ✓                       |  |  |
| CHD mortality         | Mazidi 2019 [26]         | ✓                       |  |  |
| <b>LOW-FAT DAIRY</b>  |                          |                         |  |  |
| All-cause mortality   | Guo 2017 [19]            | ✓                       |  |  |
| CVD incidence         | Guo 2017 [19]            | ✓                       |  |  |
| CHD incidence         | Soedamah-Muthu 2011 [23] | ✓                       |  |  |
|                       | Qin 2015 [21]            | ✓                       |  |  |
|                       | Alexander 2016 [22]      |                         | ✓<br>(-10% high vs. low intake)        |  |
|                       | Guo 2017 [19]            | ✓                       |  |  |





# Yoghurt

| YOGURT <b>200g</b>  |                     | Neutral Relation         | Inverse Relation<br>(% Risk Reduction) | Positive Relation<br>(% Risk Increase) |
|---------------------|---------------------|--------------------------|--|--|
| All-cause mortality | Guo 2017 [19]       | ✓                        |  |  |
|                     | Gao 2020 [32]       | ✓<br>high vs. low intake | ✓<br>(−5% per 200 g/d)                 |  |
| CVD incidence       | Alexander 2016 [22] | ✓                        |  |  |
|                     | Guo 2017 [19]       | ✓                        |  |  |
|                     | Wu 2017 [33]        | ✓<br>high vs. low intake | ✓<br>(−8% per ≥ 200 g/d)               |  |
|                     | Zhang 2020 [29]     |                          | ✓<br>(−22% high vs.<br>low intake)     |  |
| CVD mortality       | Gao 2020 [32]       | ✓<br>high vs. low intake | ✓<br>(−8% per 200 g/d)                 |  |
| CHD incidence       | Qin 2015 [21]       | ✓                        |  |  |
|                     | Alexander 2016 [22] | ✓                        |  |  |
|                     | Wu 2017 [33]        | ✓                        |  |  |
|                     | Guo 2017 [19]       | ✓                        |  |  |
|                     | Jakobsen 2021 [28]  | ✓                        |  |  |

## Cheese

| CHEESE              |                      | Neutral Relation | Inverse Relation<br>(% Risk Reduction) | Positive Relation<br>(% Risk Increase) |
|---------------------|----------------------|------------------|--|--|
| All-cause mortality | O'Sullivan 2013 [17] |                  |  |  |
|                     | Guo 2017 [19]        | ✓                |  |  |
|                     | Tong 2017 [30]       | ✓                |  |  |
| CVD incidence       | Alexander 2016 [22]  | ✓                |  |  |
|                     | Chen 2017 [31]       | ✓<br>per 50 g/d  | ✓<br>(-10% high vs.<br>low intake)     |  |
|                     | Guo 2017 [19]        |                  | ✓<br>(-2% per 10 g/d)                  |  |
|                     | Zhang 2020 [29]      |                  | ✓<br>(-13% high vs.<br>low intake)     |  |
| CVD mortality       | O'Sullivan 2013 [17] | ✓                |  |  |
| CHD incidence       | Qin 2015 [21]        |                  | ✓<br>(-16% high vs.<br>low intake)     |  |
|                     | Alexander 2016 [22]  |                  | ✓<br>(-14% per 50 g/d)                 |  |
|                     | Chen 2017 [31]       |                  | (-10% per 50 g/d)                      |  |
|                     | Guo 2017 [19]        | ✓                |  |  |
|                     | Jakobsen 2021 [28]   |                  | ✓<br>(-4% per 20 g/d)                  |  |



# Making sense of it all

1. Food matrix
2. Changes in particle size
3. Composition of replacement food
4. Role of inflammation
5. Fermentation
6. Dose-response effect



# Cheese nutrient matrix



# Cheese nutrient matrix




Dyslipidemia

Insulin  
resistance

Subclinical  
inflammation

Vascular  
dysfunction

Impaired  
coagulation



Obesity

Hypertension

Inactivity


Smoking

Alcohol

Unhealthy diet

# Particle size

- Although intake of SFA in **dairy products** leads to an increase in LDL-cholesterol, it does not increase the amount of small, dense particles, but rather the formation of **larger LDL particles**.
- Larger LDL particles are less atherogenic and thus less strongly linked to CVD due to
  - higher affinity for LDL receptors
  - decreased susceptibility to oxidation



# Composition of replacement food



## Replacing 5% energy from dairy fat with equivalent energy from other sources:

- Vegetable fat
  - 10% reduced risk
- PUFA
  - 24% reduced risk
- CHO, whole grain
  - 28% reduced risk
- Other animal fat
  - 6% increased risk

### A CVD

Vegetable fat (5%)

Other animal fat (5%)

Total PUFA (5%)


n-6 (5%)

a-Linolenic acid (0.3%)

Marine n-3 (0.3%)

Carbohydrate from whole grains (5%)

Carbohydrate from refined starches  
& added sugars (5%)



# Effect on inflammation



- The presence of low-grade inflammation are linked to the development of CVD, MS, T2DM
- Long-chain SFA [palmitic (C16:0) and stearic (C18:0) acid] found in dairy products, have pro-inflammatory effects.
- However, intake of dairy
  - leads to lower levels of CRP, TNF $\alpha$ , IL6 and IL13
  - a neutral or anti-inflammatory effect on inflammation
- A recent systematic review assessed 16 studies conducted in healthy individuals and those with MS and Type 2 DM to determine the **effect of dairy intake on inflammatory markers**:
  - No pro-inflammatory effect associated with the consumption of milk or dairy products
  - Long-term dairy intake showed a weak anti-inflammatory effect

# Role of fermentation and fermented foods




- Fermentation assists with reducing inflammation
  - Platelet-activating factor (PAF) is a pro-inflammatory phospholipid and dairy contains PAF inhibitors. As the level of fermentation increases, the PAF inhibitor activity increases.
- Unique nutrient matrix in fermented foods, as they also contain other nutrients with beneficial properties
- Bacterial fermentation results in the production of SCFA, especially butyrate:
  - improve gut health
  - regulate cholesterol metabolism
  - appetite regulation
  - anti-inflammatory properties



# Dose-response effect

- **Non-linear inverse** association between **cheese** consumption and risk for CVD
  - largest risk reductions at consumption of approximately 40 g/d






# Dose-response

Review

## Consumption of Dairy Foods and Cardiovascular Disease: A Systematic Review


Annalisa Giosuè <sup>1,†</sup> , Ilaria Calabrese <sup>1,†</sup> , Marilena Vitale <sup>1</sup> , Gabriele Riccardi <sup>1</sup> and Olga Vaccaro <sup>2,\*</sup> 

| Portion size | Risk reduction |
|--------------|----------------|
| 10 g per day | 2%             |
| 20 g per day | 4%             |
| 50 g per day | 10-14%         |




# Dose-response

- For **healthy individuals with a normal serum cholesterol** level:
  - Total dairy intake (full-fat or low-fat products): up to 200g per day
  - Milk intake: up to 200ml per day
  - Yoghurt intake: up to 200g per day
  - Cheese consumption: up to 50g per day









# Food intake globally



# Conclusion

Review

## Consumption of Dairy Foods and Cardiovascular Disease: A Systematic Review

Annalisa Giosuè <sup>1,†</sup> , Ilaria Calabrese <sup>1,†</sup> , Marilena Vitale <sup>1</sup> , Gabriele Riccardi <sup>1</sup> and Olga Vaccaro <sup>2,\*</sup> 

### 5. Conclusions

This study highlights the complexity of the relationship between different dairy foods and cardiovascular diseases as well as their risk factors. Altogether, the results indicate that the association of dairy intake with cardiovascular risk is largely driven by the food type (i.e., cheese, yogurt, milk). These findings may inform dietary recommendations for CVD prevention by allowing healthy people with normal plasma cholesterol levels a more liberal consumption of up to 200 g/day of total dairy foods (including milk, cheese, and yogurt), irrespective of being full or low fat. Within this amount of consumption, fermented dairy should be preferred (i.e., one generous serving/day of yogurt or three small servings/week of cheese).

# Conclusion

- Intake of dairy products provides different results
  - Fat content and dairy source
  - Food matrix – synergistic effect of nutrients
- Total dairy intake as risk factor for CVD
  - Protective to neutral effects
  - No harmful effects
  - Focus on low-fat guidelines not evidence-based, as there is no proof that regular / high-fat dairy intake within recommended intake levels is harmful in low-risk individuals



**Thank You**

[rb@sun.ac.za](mailto:rb@sun.ac.za)

Thank you to our sponsors!



*Dairy Cheese Ingredients and  
Natural Colours to the Food industry*

*REDA Chemicals Group*





Thank you!